Table 2 Summary of study details and patient characteristics from recent “sandwich” regimens

Lupe [6]

P

paclitaxel/carboplatin

43

IIIA-IVB

37

35

7

6

Geller [7]

P

docetaxel/carboplatin

41

59

IIIA-IVB

78

10

2

Einstein [8]

P

ifosfamide/cisplatin

27

I-IV uterine carcinosarcoma

100

Fields [9]

P

paclitaxel/platinum

30

69(45–82)

I-IV uterine papillary serous carcinoma (UPSC)

100

Secord [10]

R

paclitaxel/carboplatin 79 %

45

62(35–83

III-IV

48

17

5

28

Geller [11]

R

taxane/carboplatin

23

57(28–78)

IIA-IVB(78 %III,13 %IV)

43

52

4

Abaid [12]

R

paclitaxel/carboplatin

32

67

IA-IVA

59

13

9

9

Lan [13]

R

docetaxel/carboplatin

35

53(23–69)

IIIA-IVB

83

Dogan [5]

R

paclitaxel/carboplatin

11

63(36–83)

IIIC

73

18

9